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Abstract. 
 
Although importin 
 
a
 
 (Imp 
 
a
 
) has been 
shown to act as the receptor for basic nuclear localiza-
tion signals (NLSs) and to mediate their recruitment to 
the importin 
 
b
 
 nuclear import factor, little is known 
about the functional domains present in Imp 
 
a
 
, with the 
exception that importin 
 
b
 
 binding is known to map 
 
close to the Imp 
 
a
 
 NH
 
2
 
 terminus. Here, we demon-
strate that sequences essential for binding to the CAS 
nuclear export factor are located near the Imp 
 
a
 
 
COOH terminus and include a critical acidic motif.
Although point mutations introduced into this acidic 
motif inactivated both CAS binding and Imp 
 
a
 
 nuclear 
export, a putative leucine-rich nuclear export signal 
proved to be neither necessary nor sufficient for Imp 
 
a
 
 
nuclear export. Analysis of sequences within Imp 
 
a
 
 that 
bind to the SV-40 T antigen NLS or to the similar LEF-1 
NLS revealed that both NLSs interact with a subset of 
the eight degenerate armadillo (Arm) repeats that form 
the central part of Imp 
 
a
 
. However, these two NLS-
binding sites showed only minimal overlap, thus sug-
gesting that the degeneracy of the Arm repeat region 
of Imp 
 
a
 
 may serve to facilitate binding to similar but 
nonidentical basic NLSs. Importantly, the SV-40 T NLS 
proved able to specifically inhibit the interaction of Imp 
 
a
 
 with CAS in vitro, thus explaining why the SV-40
T NLS is unable to also function as a nuclear export
signal.
Key words: importin 
 
a
 
 • nuclear export • nuclear im-
port • nuclear localization signal
 
N
 
uclear
 
 import of proteins bearing a nuclear local-
ization signal (NLS)
 
1
 
 of the basic type first de-
fined in SV-40 T antigen and nucleoplasmin is de-
pendent on two cellular factors termed importin 
 
a
 
 (Imp 
 
a
 
)
or karyopherin 
 
a
 
 and importin 
 
b
 
 (Imp 
 
b
 
) or karyopherin
 
b
 
1 (for review see Izaurralde and Adam, 1998; Mattaj and
Englmeier, 1998; Weis, 1998). Imp 
 
a
 
 functions as the NLS
receptor (Görlich et al., 1994; Weis et al., 1995) and also
directly binds to Imp 
 
b
 
 via a specific domain, located be-
tween residues 10 and 55, termed the Imp 
 
b
 
 binding (IBB)
domain (Görlich et al., 1996
 
a
 
; Weis et al., 1996). The re-
sultant heterotrimeric complex is targeted to the nuclear
pore complex due to the direct interaction of Imp 
 
b
 
 with
specific nucleoporins (Görlich et al., 1995; Moroianu et al.,
1995). The heterotrimer is then translocated into the nu-
cleus via a poorly understood, energy-dependent process
that also requires the activity of the Ran GTPase and a
Ran cofactor termed NTF2 or p10 (Moore and Blobel,
1993; Nehrbass and Blobel, 1996; Paschal et al., 1996).
Once the heterotrimer reaches the nucleus, Imp 
 
b
 
 directly
interacts with GTP-bound Ran, a form of Ran that is
largely confined to the nucleus, resulting in the release of
Imp 
 
a
 
 and the NLS protein cargo (Rexach and Blobel,
1995; Görlich et al., 1996
 
b
 
; Izaurralde et al., 1997). Both
Imp 
 
a
 
 and Imp 
 
b
 
 are then separately recycled back to the
cytoplasm, where they can once again support nuclear im-
port. Although Imp 
 
a
 
 is a critical participant in basic NLS-
dependent protein import, it actually serves only as an
adapter to recruit NLS-containing proteins to Imp 
 
b
 
,
which is the true mediator of nuclear transport. This is
demonstrated by the finding that the Imp 
 
a
 
 IBB domain is
itself a potent NLS when attached to a carrier protein
(Görlich et al., 1996
 
a
 
; Weis et al., 1996) and also by the
identification of at least one other NLS that is Imp 
 
b
 
 de-
pendent but Imp 
 
a
 
 independent for nuclear import (Tru-
ant et al., 1998
 
a
 
).
Although Imp 
 
b
 
 is a member of a family of related pro-
teins, including the distinct nuclear import factor transpor-
tin and the nuclear export factors Crm1 and CAS, only
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1. 
 
Abbreviations used in this paper
 
: aa, amino acid(s); Arm, armadillo mo-
tif; 
 
b
 
-gal, 
 
b
 
-galactosidase; CMV, cytomegalovirus; GST, glutathione-
S-transferase; IBB, importin 
 
b
 
 binding domain; Imp 
 
a
 
, importin 
 
a
 
; Imp 
 
b
 
,
importin 
 
b
 
; NES, nuclear export signal; NLS, nuclear localization signal; T
NLS, SV-40 T antigen NLS.
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Imp 
 
b
 
 is believed to participate in Imp 
 
a
 
–dependent nu-
clear import processes (Izaurralde and Adam, 1998; Mat-
taj and Englmeier, 1998; Weis, 1998). On the other hand,
there are at least five different human forms of Imp 
 
a
 
 that
display significantly different tissue expression patterns
(Cortes et al., 1994; Cuomo et al., 1994; Görlich et al.,
1994; O’Neill and Palese, 1995; Weis et al., 1995; Köhler et al.,
1997; Tsuji et al., 1997; Nachury et al., 1998) and that, in
some cases, have been shown to interact differentially with
specific basic NLS sequences (Miyamoto et al., 1997; Nad-
ler et al., 1997; Sekimoto et al., 1997). As suggested by
Köhler et al. (1997), these Imp 
 
a
 
 family members are here
termed Imp 
 
a
 
1 (also termed hSRP1 or NPI-1), Imp 
 
a
 
2
(also termed Rch1, hSRP1
 
a
 
, or pendulin), Imp 
 
a
 
3 (also
termed Qip1), Imp 
 
a
 
4 (also termed hSRP1
 
g
 
), and Imp 
 
a
 
6.
These five variants, which vary in size between 521 and 538
amino acids (aa) in length, can be grouped into three Imp
 
a
 
 subfamilies consisting, respectively, of 
 
a
 
2, of 
 
a
 
1 and 
 
a
 
6,
and finally of 
 
a
 
3 and 
 
a
 
4, where proteins within one group-
ing are 
 
z
 
80% identical and proteins in different groups
are 
 
z
 
50% identical (Köhler et al., 1997; Tsuji et al., 1997).
Alignment of these five proteins has permitted a rough
structural domain organization of Imp 
 
a
 
 to be proposed
(see Fig. 1). In brief, the core of all five human Imp 
 
a
 
 pro-
teins consists of eight degenerate repeats of an 
 
z
 
42 aa, rel-
atively hydrophobic sequence termed the armadillo (Arm)
motif. Two additional conserved domains can also be iden-
tified. The first of these coincides with the IBB domain
whereas the second conserved sequence, which is rich in
acidic residues, extends from approximately residue 463–
509 (Köhler et al., 1997). Other regions of Imp 
 
a
 
, i.e., the
residues flanking the IBB and the acidic motif, tend to be
poorly conserved in the different Imp 
 
a
 
 variants and have
therefore been termed variable regions (Tsuji et al., 1997).
In addition to sequences that interact with Imp 
 
b
 
, Imp 
 
a
 
is predicted to contain a binding site(s) for basic NLS se-
quences and also a nuclear export signal (NES) to permit
its rapid return to the cytoplasm. Only in one case has the
binding site for a basic NLS been mapped, i.e., for the
RAG 1 NLS on Imp 
 
a
 
1, where binding was shown to re-
quire the Arm motifs four through seven or five through
eight (Cortes et al., 1994). Based on this result, and also on
the finding that a form of Imp 
 
a
 
1 lacking the first 77 aa
and the last 63 aa retained the ability to bind the SV-40 T
antigen NLS (T NLS), it has been suggested that basic
NLS binding maps to the Arm repeat region of Imp 
 
a
 
(Sekimoto et al., 1997). The issue of the Imp 
 
a
 
 NES is
more complex, in that Imp 
 
a
 
 has, on one hand, been pro-
posed to exit the nucleus via a leucine-rich NES located
between residues 207 and 217 in Arm repeat 3 (Boche and
Fanning, 1997), that would be predicted to be dependent
on the Crm1 nuclear export factor (Fornerod et al., 1997;
Stade et al., 1997), whereas on the other hand Imp 
 
a
 
 has
also been proposed to exit the nucleus via an unmapped
NES that is dependent on the distinct nuclear export fac-
tor CAS (Kutay et al., 1997
 
a
 
).
In this article, we have attempted to more fully define
the domain organization of the 
 
a
 
2 form of Imp 
 
a
 
 and, in
particular, to map Imp 
 
a
 
2 sequences involved in NLS
binding and nuclear export. We demonstrate that Imp 
 
a
 
2
binds to CAS, but not to Crm1, in vivo and show that CAS
binding is critically dependent on the conserved acidic do-
 
main located near the Imp 
 
a
 
 COOH terminus. Mutation
of this acidic domain is shown to block the ability of Imp
 
a
 
2 to exit the nucleus whereas mutation of the putative
Imp 
 
a
 
2 leucine-rich NES has no effect. We also demon-
strate that NLS binding by Imp 
 
a
 
2 involves not only the
Arm repeats but also the flanking variable regions and
show that different NLS sequences bind to distinct regions
within Imp 
 
a
 
2. Finally, we demonstrate that Imp 
 
a
 
 is un-
able to simultaneously bind a basic NLS and the CAS nu-
clear export factor, thus providing an explanation for why
such basic NLS sequences are unable to also function as
an NES.
 
Materials and Methods
 
Construction of Molecular Clones
 
The human CAS cDNA sequence was amplified by PCR using primers
containing unique 5
 
9
 
-BamHI and 3
 
9
 
-SalI restriction sites using pCAD/
CAS as a template (Brinkmann et al., 1995) and inserted into the
polylinker sites BamHI and SalI present in pGBT9 (Clontech Laborato-
ries, Palo Alto, CA). The resultant pGAL4/CAS plasmid is predicted to
express a fusion protein consisting of the DNA-binding domain of GAL4
(aa 1–147) fused to the NH
 
2
 
 terminus of full-length CAS. pGAL4/Imp 
 
b
 
was made by amplifying a full-length importin Imp 
 
b
 
1 cDNA, using prim-
ers that introduce BamHI sites on both ends, with plasmid pGST/Imp 
 
b
 
 as
a template (Truant et al., 1998
 
a
 
). The PCR product was then cut with
BamHI and ligated into pGBT9 digested with BamHI. The truncated
form of Imp 
 
b
 
 was made similarly, using a 5
 
9 
 
primer that starts at aa 262.
pGAL4/TNLS was made by inserting annealed oligos encoding the amino
acids 
 
NH
 
2
 
-GG
 
TPPKKKRKVEDP
 
-
 
COOH
 
 (boldfaced letters represent
the T NLS) into the restriction sites EcoRI and SalI present in pGBT9.
Plasmid pGAL4/LEF-1 encodes the GAL4 DNA-binding domain fused
to aa 297–399 of LEF-1, which includes the LEF-1 NLS, and has been de-
scribed (Prieve et al., 1996).
A cDNA encoding full-length human Imp 
 
a
 
2 (Rch1) was isolated from
a human T cell cDNA library by PCR amplification with primers intro-
ducing unique EcoRI (5
 
9
 
) and XhoI (3
 
9
 
) restriction sites. This cDNA was
found to encode a predicted protein identical to the published Imp a2
(Rch1) sequence (Cuomo et al., 1994) except that residue 455 was lysine
instead of glutamic acid. The Imp a2 cDNA was attached 39 to, and in
frame with, sequences encoding the VP16 transcription activation domain
by insertion into the EcoRI and XhoI restriction sites present in pVP16
(Bogerd et al., 1995). Deletion mutants of Imp a2 were generated simi-
larly by inserting PCR products (template pVP16/Imp a2) encoding the
indicated amino acids (see Fig. 1) into the EcoRI and XhoI restriction
sites of pVP16. The sequences encoding VP16/a2M1, M2, and M3 were
generated using recombinant PCR with overlapping primers that intro-
duced the missense mutations indicated in Fig. 1. The outside primers
used in the second round of amplification were designed to allow efficient
in-frame insertion into pVP16. The integrity of the resultant Imp a2
clones was confirmed by sequencing, using an Abi Prism 377 DNA Se-
quencer (Perkin Elmer Corp., Foster City, CA).
The pVP16/Imp a4 expression plasmid contains a cDNA encoding full-
length human Imp a4 (hSRP1g) (Köhler et al., 1997) isolated from a hu-
man HeLa cDNA library (Clontech Laboratories) by PCR amplification
using primers that introduced flanking 59 EcoRI and 39 BglII restriction
sites. The resulting PCR product was inserted into pVP16 digested with
EcoRI and BamHI. The pVP16/Imp a1 expression plasmid contains a
cDNA encoding full-length Imp a1 (hSRP1) (Weis et al., 1995) obtained
by PCR amplification using the same HeLa cDNA library. The primers
used introduced unique 59 EcoRI and 39 BamHI restriction sites that were
then used to insert the open reading frame into the EcoRI and BamHI re-
striction sites present in the pVP16 polylinker.
The plasmid pSG424 (Sadowski and Ptashne, 1989) was used for con-
struction of plasmids that allow expression of GAL4(1–147) fusion pro-
teins in mammalian cells. To generate pGAL4/CAS, a cDNA sequence
encoding full-length CAS was obtained by digesting the yeast expression
plasmid pGAL4/CAS with BamHI and SalI and inserting the resultant
fragment into pSG424 cut with the same restriction enzymes. Plasmid
pGAL4/ImpbD1/261 was made by inserting a BamHI fragment derivedHerold et al. Importin a Domain Organization 311
from the corresponding yeast expression plasmid into the BamHI restric-
tion site present in pSG424.
The VP16 fusion proteins used in the mammalian system were gener-
ated by inserting PCR products encoding Imp a2 or its mutant forms into
pBC12/cytomegalovirus (CMV)/VP16 (Bogerd et al., 1995) using the re-
striction sites NcoI and BglII. Templates for amplification were the corre-
sponding cDNA sequences present in the yeast expression plasmids. The
resulting plasmids allow the expression of Imp a2 fusion proteins that con-
tain a COOH-terminal VP16 domain. The mammalian indicator plasmid
pG6(231)HIVLTRDTARCAT, referred to here as pG6/CAT, and the in-
ternal control plasmid pBC12/CMV/b-Gal have been described (South-
gate and Green, 1991; Fridell et al., 1997), as have the mammalian two-hybrid
expression constructs pGAL4/Crm1, pRev/VP16, and pRevM10/VP16
(Bogerd et al., 1995).
The pGST/a2/HIS expression plasmid, encoding wild-type Imp a2
fused to glutathione-S-transferase (GST) (NH2 terminal) and a 63 His tag
(COOH terminal), was made by insertion of cDNA sequences encoding
wild-type Imp a2 into pGEX 4T-1 (Pharmacia Biotech, Piscataway, NJ)
using the restriction sites EcoRI and XhoI. A plasmid encoding a GST/
a2M1/HIS fusion protein was constructed using the identical approach. In
both cases, the COOH-terminal 63 His tag was added by cutting the plas-
mid with the restriction enzymes PpuMI and XhoI. This digestion re-
moves a fragment encoding the last 5 aa of Imp a2 including the stop
codon. Then annealed oligos encoding the missing 5 aa, and a 63 His tag
followed by a stop codon were inserted. The inserted sequence also con-
tained an EcoRI and a SalI restriction site between the last aa of Imp a2
and the His tag. The pGST/a2 M2/HIS plasmid, containing the M2 mis-
sense mutation of Imp a2, was generated by inserting a NgoM1/PpuM1
fragment from the yeast expression plasmid pVP16/M2 into the same re-
striction sites present in pGST/a2/HIS. Plasmid pGST/a2D491/529/HIS
was made by PCR amplification of a cDNA sequence encoding Imp a2 aa
364–490, using primers that contained a 59 NgoMI restriction site as well
as 39 EcoRI and SalI restriction sites followed by a 63 HIS tag, a stop
codon, and an XhoI site. This PCR product was then inserted into GST/
a2/HIS digested with NgoMI and XhoI.
Plasmid pHT-CAS was constructed by BamHI and SalI digesting plas-
mid pGAL4/CAS and ligating the resulting fragment into BamHI-SalI–
digested pQE32 vector (QIAGEN, Santa Clarita, CA). The resultant con-
struct encodes the CAS protein with an NH2-terminal 6-His tag. Plasmids
pGSTa2 and pGSTa2M2 were constructed similarly by digesting plasmids
pVP16/Impa2 and pVP16/Impa2M2 with EcoRI and XhoI and ligating
the resulting fragments into EcoRI-XhoI–digested pGEX 4T-1 (Pharma-
cia Biotech). The resulting plasmids encode the Impa2wt or Impa2M2
protein fused to GST separated by a thrombin protease cleavage site.
Plasmid pGSTRanQ69L has been described (Truant et al., 1998a).
Yeast Two-hybrid Analysis
The interaction between Impa1, Impa4, and wild-type and mutant forms
of Imp a2, on the one hand and CAS, wild-type and D1/261-deleted Imp
b, the LEF-1 NLS and the T NLS on the other, was assayed using the
yeast two-hybrid protein interaction system (Fields and Song, 1989). Plas-
mids encoding the appropriate GAL4(1–147) DNA-binding domain and
VP16 fusion proteins were transformed into the yeast indicator strain
Y190 (Harper et al., 1993) by standard techniques. After 3 d of growth at
308C on selective culture plates, double transformants were transferred to
selective medium. The following day, cultures were assayed for b-galac-
tosidase (b-gal) activity (Bogerd et al., 1995). However, due to the slower
growth of yeast cells containing pGAL4/LEF-1(297–399), these transfor-
mants were incubated for 5 d on plates and liquid cultures were incubated
for z36 h at 308C before b-gal activity was measured.
Mammalian Two-hybrid Assay
Human 293T cells were maintained in Dulbecco’s modified Eagle’s me-
dium supplemented with 5% fetal calf serum, gentamycin, fungizone, and
glutamine. On the day before transfection, cells were seeded in 6-well
dishes at a density of 3 3 105 cells per 35-mm well. The cells were trans-
fected with 0.5 mg of the reporter plasmid pG6/CAT, 2 mg of the plasmids
encoding the appropriate VP16 and GAL4 fusion proteins, and 100 ng of
pBC12/CMV/b-gal using the calcium phosphate method. At z48 h post-
transfection, cell lysates were prepared and CAT and b-gal levels quanti-
fied as described (Bogerd et al., 1995).
Recombinant Protein Expression
GST fusion proteins were expressed in the Escherichia coli strains BL21
(Novagen, Madison, WI) (GST/a2/HIS, GST/a2 M2/HIS) or TOPP1
(Stratagene, La Jolla, CA) (GST/a2 M1/HIS, GST/a2D491/529/HIS).
Overnight cultures were diluted 1:5 and then grown for 4.5 h without in-
duction. Cells were collected by centrifugation, resuspended in GST
buffer (20 mM Hepes, pH 7.4, 0.5 M NaCl, 10% glycerol) and lysed by
sonication. The lysate was centrifuged and the GST fusion protein present
in the supernatant absorbed to glutathione–Sepharose 4B (Pharmacia
Biotech.), washed with GST buffer, and then eluted with elution buffer
(13 PBS, 10 mM glutathione, pH 7.4). The proteins were then concen-
trated in a centricon-10 concentrator (Amicon, Beverly, MA).
For use in affinity chromatography assays, wild-type and M2 mutant
forms of Impa2, as well as the Q69L mutant of Ran, which does not sup-
port hydrolysis of bound GTP (Bischoff et al., 1994), were expressed, puri-
fied, and cleaved as described (Truant et al., 1998a). CAS protein was ex-
pressed in the E. coli DH5a strain. After 2 h of growth of a 1:10 dilution
from an overnight culture in 2XYT medium at 378C, the culture was in-
duced with 0.5 mM isopropylthio-b-d-galactoside (IPTG) for 4 h at 378C.
After harvesting by centrifugation, the cells were lysed by sonication, cen-
trifuged, and then the supernatant was saved. The pellet was detergent ex-
tracted (B-Per; Pierce Chemical Co., Rockford, IL), recentrifuged, and
the second supernatant was incubated along with the original supernatant
with nickel-agarose beads (QIAGEN). The His-tagged CAS protein was
eluted from the nickel-agarose beads on an imidazole gradient and then
further purified on a Q–Sepharose ion exchange column (Pharmacia Bio-
tech). SV-40 T NLS peptides were made synthetically. The peptide se-
quences used were: T NLS wild type, 125-YPKKKRKVEDP-135 and T
NLS mutant(K128T), 125-YPKtKRKVEDP-135.
Protein Affinity Chromatography
Purified wild-type and M2 mutant Imp a2 proteins were covalently cou-
pled at a 6 mg/ml concentration to active ester-agarose beads (Affi-10;
Bio-Rad Laboratories, Hercules, CA). The protein-coupled beads were
then used to make 10-ml columns in 100-ml borosilicate glass micropipets.
Approximately 4 mg of CAS protein was preincubated on ice with 6 mg
RanQ69L and 1 mM GTP in ACB buffer (10 mM Hepes, pH 7.4, 10%
glycerol, 50 mM NaCl, 1 mM MgCl2) in a 75-ml final volume. This entire
mix was then loaded onto microcolumns containing either wild-type or
M2 mutant Imp a2. The columns were then washed with 6-column vol of
100 mM NaCl ACB buffer and finally eluted with 5-column vol 500 mM
MgCl2. The entire bound fraction was analyzed by 10% SDS-PAGE
(Ready-gels; Bio-Rad Laboratories) and visualized by Coomassie blue
staining (R-250, Life Technologies, Inc.). For SV-40 T NLS peptide com-
petition experiments, 100 mg (z100 fold molar excess) of SV-40 T NLS
wild-type or mutant peptides were mixed with the CAS/RanQ69L/GTP
mixture before loading onto the Impa2 columns.
Mammalian Cell Microinjection
HeLa cells were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 5% fetal calf serum, gentamycin, fungizone, and
glutamine. 2 d before microinjection, HeLa cells were seeded onto CELL-
ocate microgrid coverslips (Eppendorf Scientific, Hamburg, Germany) at
a density of 2 3 105 cells per 35-mm dish. To increase the percentage of
multinucleated cells, cultures were serum starved overnight. The next day,
cells were replenished with serum containing media 4–6 h before microin-
jection. The proteins (final concentration in PBS z2 mg/ml) were coin-
jected with a rhodamine-conjugated goat IgG tracer (final concentration
1.5 mg/ml; Cappel Laboratories, Malvern, PA) to verify the site of injec-
tion. After injection, cells were incubated at 378C for 35 min and then
fixed with 3% paraformaldehyde in PBS (Fridell et al., 1997). The GST
fusion protein was visualized by indirect immunofluorescence using a
polyclonal affinity-purified rabbit anti–GST antibody and fluorescein-
conjugated donkey anti–rabbit antiserum. Cellular localization of the in-
jected proteins was determined using a Leica DMRB fluorescence micro-
scope (Leica USA, Deerfield, IL) at a 1003 magnification.
Results
As noted above, Imp a is predicted to interact with Imp b,
with a range of different basic NLS sequences and with at
least one nuclear export factor. To test whether this pre-The Journal of Cell Biology, Volume 143, 1998 312
diction is correct, we asked whether the a2 (RchI) form of
Imp a would be able to interact with Imp b, with CAS, and
with two different NLS sequences, derived from the T
NLS (Kalderon et al., 1984) or the transcription factor
LEF-1 (Prieve et al., 1996), in the yeast two-hybrid pro-
tein–protein interaction assay.
As shown in Table I, full-length Imp a2 proved able to
specifically interact with full-length human CAS and with
both the T NLS and the LEF-1 NLS, as shown by the
readily detectable activation of b-gal expression in cells
expressing a VP16/Imp a2 fusion protein and the appro-
priate GAL4 fusions. However, Imp a2 failed to interact
with the GAL4 DNA-binding domain itself or with full-
length human Imp b. This latter result is expected, as the
interaction of Imp b with Ran-GTP in the nucleus is pre-
dicted to block Imp a binding (Rexach and Blobel, 1995;
Görlich et al., 1996b). We therefore removed most of the
Ran-GTP–binding domain of Imp b, which is known to be
located at the Imp b NH2 terminus (Chi and Adam, 1997;
Kutay et al., 1997b), by deletion of Imp b residues 1–261.
The resultant Imp bD1/261 protein proved able to effec-
tively interact with Imp a2 in the two-hybrid assay (Table I).
As noted above, there are five known forms of Imp a
that can be subdivided into three families consisting of a1
and a6, a3 and a4, and finally a2. To test whether the abil-
ity of a2 to interact with CAS and Imp b was a general
property of these family members, we asked whether a1
and a4 would also be able to interact with these two pro-
teins in the yeast two-hybrid assay. As shown in Table II,
both Imp a1 and Imp a4 interacted strongly with the
GAL4/Imp–bD1/261 fusion protein and less strongly, but
still detectably, with CAS. We therefore conclude that
both Imp b and CAS binding are conserved properties of
Imp a family members and would therefore be predicted
to map to sequences conserved among Imp a family mem-
bers.
Protein Interaction Domains of Imp a2
We next constructed a series of deletion mutants of Imp
a2 in the context of the Vp16/Imp a2 fusion protein and
determined whether these would retain the ability to bind
to ImpbD1/261, CAS, and to the T NLS and LEF-1 NLS.
It should be noted that the T NLS (NH2-PKKKRKVE-
COOH) and the LEF-1 NLS (NH2-KKKKRKREK-
COOH) are both lysine-rich NLS sequences that have
been previously shown to specifically interact with full-
length Imp a (Prieve et al., 1996; Sekimoto et al., 1997).
The structure of the 19 deletion mutants of Imp a2 used
in these experiments is shown in Fig. 1. These consist of
four mutants progressively deleted from the NH2 termi-
nus, eight mutants deleted progressively from the COOH
terminus, and seven mutants deleted internally, starting
from residue 137. It is important to note that every one of
these mutants gave rise to a readily detectable interaction
with at least one of the four protein targets described
above (Table III), thus demonstrating that each mutant fu-
sion protein was expressed at functional levels in the yeast
cell nucleus.
As expected, deletion of the first 53 or 80 aa of Imp a2,
which includes the IBB domain (Görlich et al., 1996a;
Weis et al., 1996), blocked binding to Imp b but had at
Table I. Interaction of Imp a2 with Various Cellular Targets 
Measured by Yeast Two-hybrid Analysis
DNA-binding domain hybrid
b-gal activity (mOD/ml)*
VP16 VP16/Imp a2
GAL4 5 7
GAL4/Imp b 38
GAL4/Imp bD1/261 4 1,198
GAL4/CAS 3 434
GAL4/T-NLS 4 1,211
GAL4/LEF-1 (297–399) 4 130
*Data are given as milli optical density units per ml of yeast extract observed in yeast
transformants expressing the indicated GAL4 and VP16 fusion proteins. Induced
b-gal activities were determined as described previously (Bogerd et al., 1995) and are
representative of values obtained in three independent experiments.
Table II. Both CAS and Imp b Binding Are Conserved among 
Different Imp a Family Members
DNA-binding domain hybrid
b-gal activity (mOD/ml)
VP16 VP16/Imp a1 VP16/Imp a4
GAL4 5 4 3
GAL4/Imp b 34 1
GAL4/Imp bD1/261 4 2,350 1,850
GAL4/CAS 3 101 174
Protein interactions were analyzed in yeast cells using the two hybrid assay, as de-
scribed in Table I. Data shown are representative of three independent experiments.
Table III. Protein Interaction Profiles of a Panel of
Imp a2 Mutants
Activation domain
hybrid
Relative b-gal activity
GAL4/CAS
GAL4/Imp
bD1/261 GAL4/LEF-1 GAL4/T NLS
VP16/a2D1/53 1 2 11 1
VP16/a2D1/80 1 2 11 1
VP16/a2D1/104 1 2 11 2
VP16/a2D1/138 1 2 11 2
VP16/a2D501/529 11 11 1 1 1
VP16/a2D496/529 21 11 1 1 1
VP16/a2D491/529 2 1 11 1
VP16/a2D471/529 21 1 1 1
VP16/a2D449/529 21 2 1 1
VP16/a2D441/529 21 2 1
VP16/a2D363/529 21 1 2 1 1
VP16/a2D321/529 21 2 2
VP16/a2D136/249 11 11 1 2
VP16/a2D136/278 11 11 2 2
VP16/a2D136/320 11 11 2 2
VP16/a2D136/365 11 1 2 2
VP16/a2D136/382 1/2 11 2 2
VP16/a2D136/394 21 1 2 2
VP16/a2D136/406 21 1 2 2
VP16/a2M1 11 11 11 11
VP16/a2M2 21 11 1 1 1
VP16/a2M3 1/2 11 11 11
Protein interaction data were determined by yeast two-hybrid analysis, as described in
Table I, and are categorized relative to the level seen with the wild-type VP16/Imp a2
fusion protein as follows: 11, .40% of wild-type a2; 1, 15–40% of wild-type; 1/2,
2–5% of wild-type; 2, ,2% of wild-type.Herold et al. Importin a Domain Organization 313
most a modest effect on binding to CAS, T NLS, and LEF-1
NLS (Table III). Surprisingly, further NH2-terminal dele-
tion, to either residue 104 or residue 138, also entirely
blocked T NLS binding by Imp a2, although LEF-1 NLS
and CAS binding remained readily detectable. Therefore,
these data demonstrate that the LEF-1 and T NLSs bind
to distinguishable domains in Imp a2 and further demon-
strate that the sequences essential for T NLS binding ex-
tend NH2 terminal to the first Arm motif of Imp a2.
Progressive deletion from the COOH terminus of Imp
a2 demonstrated that residues located between 496 and
501, i.e., within the conserved acidic domain, were critical
for CAS binding but dispensable for binding to Imp b and
to both the LEF-1 and T NLS (Table III). Further deletion
of Imp a2 residues between positions 449 and 471 resulted
in the additional loss of LEF-1 NLS binding but did not af-
fect binding to Imp b or the T NLS. In fact, deletion of ad-
ditional residues up to position 363, i.e., deletion of Arm
repeats 7 and 8, failed to inhibit either T NLS or Imp b
binding, although both LEF-1 NLS binding and CAS bind-
ing remained undetectable. However, deletion of residues
321–363, which form Arm repeat 6, did block T NLS, but
not Imp b, binding by Imp a2 (Table III). These data
therefore further confirm the distinction between the Imp
a2 sequences required to bind the T NLS and LEF-1 NLS
and demonstrate that the sequences required for LEF-1
binding extend COOH terminal to the eighth and last
Arm motif.
All internal deletion mutations, starting with VP16/
a2D136/249, were negative for T NLS binding (Table III).
However, these mutants did permit the NH2-terminal bor-
der of the CAS-binding domain of Imp a2 to be mapped
to between 382 and 394 for weak CAS binding or between
365 and 382 for strong binding. Importantly, this mapping
therefore excludes any role for the putative leucine-rich
NES sequence, located between residues 207 and 217 in
Imp a2, in mediating binding to CAS. These data also map
the NH2 terminus of the LEF-1 NLS binding sequence in
Imp a2 to between residues 249 and 278, i.e., to at least
145 residues COOH terminal to the border of the se-
quences required for binding the functionally equivalent T
NLS (Table III).
The data derived from the deletion mutants presented
in Fig. 1 demonstrate that CAS binding is dependent on
Imp a2 sequences located in the conserved COOH-termi-
nal acidic domain but independent of the putative leucine-
rich NES located between 207 and 216 (Boche and Fan-
ning, 1997). To more fully confirm this hypothesis, we
mutated the leucine-rich sequence present in Imp a2 by
substitution of alanine residues for leucines to generate
mutant M1 (Fig. 1). Comparable mutations have previ-
ously been shown to entirely block NES function for sev-
eral leucine-rich NESs (Malim et al., 1991; Wen et al.,
1995). Similarly, we also substituted alanine in place of
conserved residues located in the Imp a2 acidic domain to
generate Imp a2 mutants M2 (residues 469–474) and M3
(residues 476 –481) (Fig. 1). These missense mutants were
then tested for binding to Imp b, CAS, the T NLS and the
LEF-1 NLS by two-hybrid analysis. As shown in Table III,
the M1 mutation had no effect on Imp a2 binding to any of
these four protein targets. In contrast, the M2 mutation
eliminated, and the M3 mutation strongly inhibited, CAS
binding without affecting binding to Imp b, T NLS, or
LEF-1 NLS. These data therefore confirm that the con-
served Imp a2 acidic domain is critical for specific CAS
binding in vivo.
Imp a2 Binds to CAS but Not to Crm1
We next asked whether Imp a2 would be able to bind to
CAS, or to the leucine-rich NES-specific nuclear export
factor Crm1 (Fornerod et al., 1997; Stade et al., 1997), in
mammalian cells using a previously described mammalian
version of the two-hybrid assay (Bogerd et al., 1995). In
this assay, fusions of the GAL4 DNA-binding domain to
full-length human Crm1 or CAS, or to the D1/261 deletion
mutant of Impb, were coexpressed in the mammalian cell
nucleus together with fusion proteins consisting of the
VP16 transcription activation domain linked to wild-type
or M1 mutant forms of Impa2 or to wild-type or M10 mu-
tant forms of the human immunodeficiency virus type 1
Rev protein. The Rev protein is known to contain an ac-
tive leucine-rich NES whereas the M10 Rev mutant en-
codes a defective form of this NES (Malim et al., 1989;
Fischer et al., 1995; Wen et al., 1995).
Figure 1. Structure of Imp a2 mutants. The conserved structural
domains present in all Imp a family members are shown at the
top of the figure whereas the structure of the Imp a2 deletion and
missense mutants used in this work are given below. The names
of the deletion mutants indicate which NH2 residues are missing
in the particular mutant protein. The location of the M1, M2, and
M3 missense mutations within Imp a2, and the identity of the in-
troduced mutation, are given at the bottom.The Journal of Cell Biology, Volume 143, 1998 314
As shown in Fig. 2, we observed a readily detectable in-
teraction between wild-type Rev and Crm1 that was
blocked by the M10 NES mutation, but not between Rev
and either CAS or Imp b. In contrast, both the wild-type
and M1 mutant form of Imp a2 interacted strongly with
both GAL4/CAS and the GAL4 ImpbD1/261 fusion pro-
tein but failed to interact detectably with Crm1. These
data therefore suggest that Imp a2 contains a CAS-depen-
dent, but not a Crm1-dependent, NES sequence.
In addition to the mammalian two-hybrid data pre-
sented in Fig. 2, we also assessed the ability of a subset of
the a2 mutations described in Fig. 1 to interact with either
CAS or ImpbD1/261 in the mammalian nucleus. In brief,
these data (Table IV) confirmed the yeast data (Table III)
showing that the NH2-terminal border of the CAS-binding
domain in Imp a2 was located near to residue 365 and also
located the COOH-terminal border of this domain be-
tween residues 491 and 501. In addition, these data (Table
IV) revealed that both the M2 and the M3 mutant of Imp
a2 are severely inhibited for CAS, but not for Imp b, bind-
ing in the mammalian cell nucleus.
CAS-binding Domain of Imp a2 Mediates
Nuclear Export
We next wished to ask whether the ability to interact with
CAS was indeed critical for the nuclear export of Imp a2
from the mammalian cell nucleus. As described in more
detail elsewhere (Truant et al., 1998b), we have observed
that recombinant Imp a2 accumulates in the nucleus of
microinjected human cells. To demonstrate nuclear export,
we therefore mixed recombinant wild-type full-length Imp
a2 fused to GST with a rabbit IgG tracer protein and mi-
croinjected it into a single nucleus located in multinucleate
cells. If Imp a2 contains a functional NES, to go with the
NLS activity known to reside in the IBB motif, it should
export from the injected nucleus and then import into the
uninjected nuclei present in the same cell. This is indeed
precisely the activity that was seen, in that the injected
GST/Imp a2 fusion protein is redistributed to all the nu-
clei present in an injected cell (Fig. 3 B) whereas the IgG
tracer remains in the single injected nucleus (Fig. 3 A).
The same result was obtained upon injection of the M1
mutant form of full-length GST/Imp a2 into one nucleus
in a multinucleate cell (Fig. 3, D and E), thus demonstrat-
ing that a functional form of the putative leucine-rich NES
present between residues 207 and 217 in Impa2 is not re-
quired for nuclear export. In contrast, GST–Imp a2 fusion
proteins containing either the D491/529 deletion mutation
or the M2 missense mutation that knocks out CAS binding
(Tables III and IV) failed to demonstrate nucleocytoplas-
mic shuttling (Fig. 3, H and K) even though both proteins
are efficiently imported into the nucleus when injected
into the cell cytoplasm (data not shown). We therefore con-
clude that CAS binding is a critical step in the nuclear ex-
port of Imp a2 in human cells.
Imp a Is Unable to Bind CAS and the
T NLS Simultaneously
The mapping data presented in Table III, and summarized
in Fig. 4, demonstrate that the CAS-binding domain in
Imp a2 is located between residues 383 and 497 whereas
the SV-40 T NLS binding sequences are located between
residues 81 and 362. Therefore, at least in this linear repre-
sentation of the Imp a2 molecule, these binding domains
do not obviously overlap. However, if the T NLS and the
CAS nuclear export factor could bind Imp a simulta-
neously, then one might predict that proteins containing
the T NLS would be exported from the nucleus in a ter-
nary complex with Imp a and CAS just as they are im-
ported into the nucleus as a ternary complex with Imp a
and Imp b.
Figure 2. Interaction of Imp a2 and HIV-1 Rev with human nu-
cleocytoplasmic transport factors measured by mammalian two-
hybrid assay. Human 293T cells were transfected with one of the
indicated GAL4 DNA-binding domain fusion protein expression
plasmids, one of the indicated VP16 transcription activation do-
main fusion protein expression plasmids, the two-hybrid interac-
tion indicator construct pG6/CAT and finally the internal control
plasmid pBC12/CMV/b-gal. Induced CAT activities were mea-
sured at 48 h after transfection, as previously described (Bogerd
et al., 1995), and were corrected for small differences in transfec-
tion efficiency revealed by analysis of b-gal expression levels.
Table IV. Interaction of Imp a2 Mutants with CAS and Imp b 
Measured by Mammalian Two-hybrid analysis
VP16 activation domain hybrid
Relative CAT activity
GAL4/CAS GAL4/Imp bD1/261
Imp a2/VP16 11 11
a2D501/529/VP16 11 11
a2D491/529/VP16 21
a 2 D 136/249/VP16 11 1
a 2 D 136/365/VP16 1/21 1
a 2 D 136/382/VP16 21 1
a 2 D 136/406/VP16 21 1
a 2M1/VP16 11 11
a2M2/VP16 21
a 2M3/VP16 21 1
Protein interaction data were determined by mammalian two-hybrid analysis in trans-
fected human 293T cells, as described in Fig. 3. Activity is given relative to the level
seen with the wild-type Imp a2 fusion protein as follows: 11, .40% of wild-type;
1, 14–40% of wild-type; 1/2, 1–5% of wild-type; 2, ,0.2% of wild-type.Herold et al. Importin a Domain Organization 315
To test whether the T NLS and CAS can indeed bind
Imp a2 simultaneously, we performed an in vitro protein–
protein interaction assay using recombinant wild-type and
M2 mutant Imp a2 and CAS as well as Ran protein (Fig.
5). As reported previously by Kutay et al. (1997a), we ob-
served that efficient binding of Imp a by CAS only oc-
curred in the presence of the GTP bound form of Ran
(data not shown). This interaction was specific in that CAS
bound the wild-type but not the M2 mutant form of Imp
a2 in vitro (Fig. 5, B and C), thus also confirming the in
vivo data demonstrating that the Imp a2 M2 mutant
blocks CAS binding (refer to Tables III and IV). Interest-
ingly, although the NH2 terminally HIS-tagged recombi-
nant CAS protein preparation used in this analysis con-
tained a significant level of breakdown products that
presumably represent a nested set of COOH terminally
truncated forms of CAS, only the full-length form of CAS
was observed to bind to Imp a2 (Fig. 5, compare lane A
with B). This further confirms the specificity of this pro-
tein–protein interaction and suggests that sequences lo-
cated towards the CAS COOH terminus are critical for
Imp a2 binding.
To examine whether the T NLS would interfere with
CAS binding to Imp a2, we repeated this binding assay in
the presence of an z100-fold molar excess of synthetic
peptides containing either the wild-type SV-40 T NLS or a
mutant, nonfunctional form of the T NLS (K128 to T, Kal-
deron et al., 1984). As shown in Fig. 5, the wild-type T
NLS peptide entirely blocked CAS binding by Imp a2
whereas the mutant peptide had no effect. We therefore
conclude that Imp a2 is unable to simultaneously bind to
both CAS and the T NLS.
Discussion
A major goal of the research described in this article was
the determination of whether Crm1 (Boche and Fanning,
1997) or CAS (Kutay et al., 1997a) was required for the
nuclear export of Imp a and if the latter, the identifica-
Figure 3. CAS mediates the
nuclear export of Imp a2.
Recombinant fusion pro-
teins consisting of GST linked
to full-length, wild-type Imp
a2 and to the M1, D491/529
or M2 mutants of Imp a2,
were purified from bacteria,
mixed with a rhodamine-con-
jugated rabbit IgG tracer,
and then microinjected into a
single nucleus in a multinu-
cleate HeLa cell. Subcellular
localization of the injected
proteins was determined at
35 min after injection by
double-label immunofluores-
cence microscopy, as previ-
ously described (Fridell et
al., 1997). GST fusion pro-
teins able to undergo nucleo-
cytoplasmic shuttling to the
uninjected nuclei present in
the same cell (B and E) must
contain a functional NES
whereas mutants lacking nu-
clear export capacity (H and
K), as well as the IgG tracer
(A, D, G, and J), remain con-
fined to the single injected
nucleus.
Figure 4. Functional domain organization of Imp a2. The figure
correlates the location of the conserved structural domains of
Imp a with the approximate location of sequences in Imp a2
required for binding to Imp b, to CAS, to the LEF-1 NLS and the
T NLS. The speckled areas are essential for binding to each tar-
get while the flanking clear boxes define the ambiguity as to the
precise border of the critical Imp a2 sequences. IBB, Imp b bind-
ing motif; V, variable regions.The Journal of Cell Biology, Volume 143, 1998 316
tion and delineation of the CAS-dependent NES present
in Imp a. Using the two-hybrid assay for in vivo protein–
protein interactions, we have demonstrated that the dis-
tinct Imp a2, Imp a1, and Imp a4 forms of Imp a are all
able to specifically interact with human CAS in the yeast
two-hybrid assay (refer to Tables I and II). Using a mam-
malian two-hybrid assay, we confirmed the specific inter-
action of Imp a2 with CAS and showed that Imp a2 failed
to interact with Crm1 under conditions where the interac-
tion of Crm1 with the leucine-rich NES present in HIV-1
Rev was readily detectable (refer to Fig. 2). We therefore
conclude that Imp a can specifically bind to CAS but not
to Crm1 in vivo. By deletion and missense mutation analy-
sis (Tables III and IV), we have further demonstrated that
a proposed leucine-rich NES sequence (Boche and Fan-
ning, 1997), located within the third Arm repeat of Imp a2,
is entirely dispensable for CAS binding, which instead was
shown to largely map to a conserved acidic domain located
proximal to the COOH terminus of Imp a2 (refer to Fig.
4). Finally, we demonstrate that nucleocytoplasmic shut-
tling of Imp a2 is blocked by two distinct mutations within
the acidic domain that inhibit CAS binding but is not af-
fected by mutation of the putative leucine-rich NES (refer
to Fig. 3). We therefore conclude that the leucine-rich se-
quence present in Imp a2 Arm repeat 3 is neither neces-
sary nor sufficient for the nuclear export of Imp a2 and
suggest that the published identification of this sequence
as the Imp a NES (Boche and Fanning, 1997) is incorrect.
Rather, our data confirm the proposal by Kutay et al.
(1997a) that Imp a nuclear export is dependent on the in-
teraction of Imp a with the CAS nuclear export factor and
map the Imp a sequences required for this interaction to
the conserved Imp a acidic domain, together with some
adjacent flanking sequences (refer to Fig. 4). Although the
CAS-binding domain defined in this analysis is quite large,
being minimally z120 aa in length, it is clearly distinct in
sequence from the much smaller leucine-rich NES se-
quences recognized by the Crm1 nuclear export factor
(Fornerod et al., 1997; Stade et al., 1997).
In addition to defining sequences in Imp a2 that medi-
ate CAS binding, we wished to also determine which Imp
a2 sequences might be required for basic NLS recognition.
Surprisingly, with the exception of a manuscript that
mapped RAG1 NLS binding to Arm repeats 4–8 of Imp
a1 (Cortes et al., 1994), little had been reported about the
identity of Imp a sequences required for this critical step
in nuclear import at the time that this work was initiated.
The two basic NLS sequences chosen for analysis, the T
NLS and the LEF-1 NLS, are both lysine-rich NLS se-
quences that had been previously shown to bind to Imp a
specifically (Prieve et al., 1996; Sekimoto et al., 1997).
Analysis of the sequence requirements for T NLS and
LEF-1 NLS binding by Imp a2 produced two surprising
findings. First, the Imp a2 sequences required for binding
to these two NLS sequences were clearly distinct, with T
NLS binding mapping between Imp a2 residues 81–362
whereas LEF-1 NLS binding mapped between residues
250 and 470 (refer to Table III and Fig. 4). The second un-
expected result was that the Imp a2 sequences required
for basic NLS binding extended at least somewhat beyond
the Arm repeat sequences into flanking variable regions.
Specifically, T NLS binding required Imp a2 sequences lo-
cated NH2 terminal to residue 105, the first residue of the
first Arm repeat, whereas LEF-1 NLS binding clearly re-
quired sequences located COOH terminal to residue 447,
the last amino acid of the eighth Arm repeat (refer to Ta-
ble III and Fig. 4). These observations therefore demon-
strate that the identity of the Arm repeats required for any
given NLS interaction is likely to be quite variable and fur-
ther reveal that the Imp a Arm repeats, although critical
for basic NLS binding, are not necessarily sufficient, in
that flanking variable regions may also make an essential
contribution. In this regard, it is interesting to note that
several papers have reported that certain NLS sequences
can be bound by particular members of the Imp a family
of NLS receptors but not by others (Miyamoto et al., 1997;
Nadler et al., 1997; Sekimoto et al., 1997). As highly vari-
able regions in Imp a appear to make a significant contri-
bution to NLS binding, this result is not, in retrospect, sur-
prising.
Although the interaction of Imp b with Imp a in the cell
nucleus is blocked by Ran-GTP (Rexach and Blobel, 1995;
Görlich et al., 1996b), it has remained unclear why NLS
proteins are released by Imp a. Although it has been sug-
gested that basic NLS binding to an Imp a/Imp b het-
erodimer is of higher affinity than binding by Imp a alone
(Rexach and Blobel, 1995; Efthymiadis et al., 1998), it is
nevertheless apparent that NLS binding by Imp a can be
readily detected in the nucleus of cells under conditions
where Imp a and Imp b do not interact (refer to Tables I
and III) (Cuomo et al., 1994; Cortes et al., 1995; O’Neill et
Figure 5. Analysis of CAS binding to Imp a2 in vitro. Recombi-
nant wild-type or M2 mutant Imp a2 proteins were coupled to
agarose beads and used to construct microaffinity columns. Re-
combinant, NH2 terminally His-tagged CAS protein was preincu-
bated on ice with Ran and GTP before loading onto the columns
either directly or after addition of a 100-fold molar excess of a
wild-type or defective mutant T NLS peptide. After extensive
washing, bound proteins were eluted from the affinity columns
and analyzed by SDS-PAGE.Herold et al. Importin a Domain Organization 317
al., 1995). Why then doesn’t the NLS protein return to the
cytoplasm along with the Imp a/CAS complex in a process
analogous to its import by the Imp a/Imp b complex? One
possibility is that CAS binding and basic NLS binding by
Imp a is mediated by two distinct, mutually incompatible
Imp a protein conformations, a mechanism which has also
been invoked to explain why Imp b is unable to simulta-
neously bind to Imp a and Ran-GTP. Alternately, CAS
binding and NLS binding might simply sterically interfere
with one another. In either case, CAS binding, and hence
Imp a export from the nucleus, could only occur once the
NLS protein was released into the nucleoplasm. It has, in
fact, previously been demonstrated that CAS binds to
NLS-free Imp a preferentially, although the underlying
mechanism for this effect has remained unclear (Kutay et
al., 1997a). Although the extensive overlap between the
Imp a2 sequences that mediate binding to the LEF-1 NLS
and to CAS, respectively (refer to Fig. 4), certainly seems
consistent with the hypothesis that these protein–protein
interactions might be mutually exclusive, this is less obvi-
ous in the case of the SV-40 T NLS, which binds to Imp a2
sequences that do not obviously conflict with the CAS
binding site (refer to Fig. 4). Nevertheless, in vitro binding
analysis reveals that the SV-40 T NLS, but not a nonfunc-
tional mutant form thereof, can entirely block CAS bind-
ing by Imp a2 (refer to Fig. 5). These data demonstrate
that Imp a2 is unable to bind to the T NLS and to CAS si-
multaneously and therefore provide a mechanistic expla-
nation for the finding that the SV-40 T NLS is unable to
function as an Imp a–dependent NES.
After submission of this article, a paper was published
that bears on the issue of the functional domain organiza-
tion of Imp a2. Specifically, Conti et al. (1998) have pub-
lished the crystal structure of a truncated form of yeast
Imp  a bound to two molecules of an SV-40 T NLS peptide.
Although yeast Imp a is somewhat different in structure to
human Imp a2 (for example, it appears to contain 10
rather than 8 Arm repeats), this report is striking in that
the two T NLS peptides were found to bind to Arm re-
peats one through four and seven through nine, respec-
tively. The authors proposed that the larger, more NH2-
terminal NLS binding site was likely to be the functionally
relevant site on yeast Imp a for T NLS binding whereas
the smaller, more COOH-terminal site might instead play
a role in the recognition of bipartite NLSs, such as the one
observed in nucleoplasmin. In contrast, the data presented
in our article suggest that Imp a2 contains two distinct
binding sites for monopartite NLS sequences, with the
more NH2-terminal site being specific for NLSs equivalent
in sequence to the SV-40 T NLS whereas the more
COOH-terminal site may interact specifically with NLSs
that are similar to the LEF-1 NLS. From this perspective,
the weak binding observed by Conti et al. (1998) between
the T NLS peptide and the more COOH-terminal binding
site in yeast Imp a may therefore simply reflect the fact
that the structure of the T NLS is suboptimal for binding
to this latter site, rather than suggesting that this site is not
an autonomous binding site for other, more optimal
monopartite NLSs.
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